January 2025- SimBioSys announced the appointment of AI-driven medical device executive Stacey Stevens as its President and Chief Executive Officer. SimBioSys’ expanding portfolio and leadership in precision oncology position the company for growth as it continues to empower clinicians and improve patient care.

“As the demand for precision oncology solutions continues to grow, SimBioSys is uniquely positioned to deliver transformative impact,” said Ronnie Andrews, Chairman of the Board at SimBioSys. “Stacey’s extensive experience in healthcare innovation and proven leadership in scaling cutting-edge technologies make her an exceptional choice to lead SimBioSys into its next phase of growth.”

ALso Read : Cosmos Health appoints professor Dimitrios Trafalis as head of oncology

“SimBioSys is charting a bold path forward in precision oncology by combining scientific rigor with technological innovation to address some of the toughest challenges in cancer care,” said Vikram Chaudhery, PhD, Partner at Genoa Ventures. “Stacey’s leadership and proven success in bringing transformative image-based AI solutions to market uniquely position the company to deliver a profound impact on both clinicians and patients.”

“With a strong foundation in precision oncology, SimBioSys is transforming how cancer is diagnosed and treated, equipping clinicians with innovative technology and enabling more personalized care for patients,” said Stacey Stevens, President and CEO of SimBioSys. “I am honored to lead the company as we break new ground in oncology with an initial focus on breast cancer, the top cancer diagnosed in women worldwide.”

Stevens brings more than two decades of leadership in healthcare and medical technology, with a proven track record of driving innovation in cancer care.